New combo therapy aims to shrink tumors before stomach cancer surgery
NCT ID NCT06808971
Summary
This study is testing a treatment plan that combines an immunotherapy drug (adebrelimab) with several chemotherapy drugs for people with a type of stomach or gastroesophageal cancer that can be removed with surgery. The goal is to see if giving this combination before and after surgery helps eliminate more cancer cells and prevents the cancer from coming back. The study will measure how many patients have no cancer cells left in their tumor after treatment and how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.